May 1, 2014 — Boston Scientific Corp. has launched the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced drug-eluting stent (DES) technology system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval.
Coronary artery disease is a narrowing of blood vessels that supply blood and oxygen to the heart. Patients with coronary artery disease may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack. One treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.
The Promus Premier Stent System was developed with extensive input from interventional cardiologists and is designed to provide best-in-class acute performance and clinical outcomes. It features unparalleled visibility and low recoil, plus exceptional radial strength and fracture resistance. An enhanced low-profile delivery system is designed to facilitate precise stent delivery across challenging lesions.
The Promus Premier Stent System received CE mark and U.S. Food and Drug Administration (FDA) approvals in February and November of 2013, respectively.
For more information: visit www.bostonscientific.com